Kevin Campbell was named chief information officer of the Translational Genomics Research Institute, part of City of Hope.
City of Hope has received a $25 million gift from Julia and George Argyros, longtime City of Hope supporters.
Lynda Carter Altman and Robert AltmanThe Translational Genomics Research Institute, part of City of Hope, formed a partnership with actress, singer-songwriter, and advocate, Lynda Carter Altman, to accelerate diagnostics and treatments, including precision medicine approaches, for secondary acute myeloid leukemia.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
Stand Up To Cancer formed three teams investigating treatments for Non-Small Cell Lung Cancer and Ewing sarcoma, including a Lung Cancer Health Equity SU2C Catalyst Research Team with support from Bristol Myers Squibb and two SU2C Catalyst Research Teams with support from Jazz Pharmaceuticals.
Stephanie Herron was named chief development officer of Stand Up To Cancer. In this newly created position, she will be responsible for the growth and development of SU2C’s fundraising strategy, focusing on major gifts, corporate philanthropy, digital engagement, and innovation.
Pedro Torres-Ayuso was named assistant professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University. In addition to his primary position at Temple, Torres-Ayuso will hold a dual appointment in the molecular therapeutics research program at Fox Chase Cancer Center.
Anthony M. Villano was hired as a clinical instructor in the Department of Surgical Oncology at Fox Chase Cancer Center.
Hayan LeeMichael ScottHayan Lee was named an assistant professor in the Cancer Signaling and Epigenetics research program and the Cancer Epigenetics Institute at Fox Chase Cancer Center.
The Mays Cancer Center at UT Health San Antonio and Evestra Inc., a San Antonio-based biopharmaceutical company, have been awarded a five-year, $3.3 million Academic Industry Partnership grant from NIH for the research and development of a drug targeting ovarian cancer, EC359. It is the first grant of this kind awarded to The University of Texas Health Science Center at San Antonio.
